loading page

A case report of rhabdomyolysis caused by the use of roxadustat in the treatment of caused by renal anemia
  • qin yang,
  • xin wang
qin yang
Affiliated Zhongshan Hospital of Dalian University
Author Profile
xin wang
Affiliated Zhongshan Hospital of Dalian University
Author Profile

Peer review status:UNDER REVIEW

27 May 2020Submitted to International Journal of Clinical Practice
01 Jun 2020Assigned to Editor
01 Jun 2020Submission Checks Completed
02 Jun 2020Reviewer(s) Assigned
25 Jun 2020Review(s) Completed, Editorial Evaluation Pending


More than 1.2 million people died from chronic kidney damage (CKD) globally, in 2017. Anemia is a common complication of CKD. Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor that stimulates erythropoiesis and regulates iron metabolism. Roxadustat is often used to treat anemia caused by renal diseases. Its adverse effects include high blood pressure, myocardial infarction, heart failure, high potassium, and dizziness; however, there are no reports about rhabdomyolysis associated with roxadustat. One of our patients developed rhabdomyolysis after he was administered roxadustat to treat anemia caused by chronic renal failure. Physicians should be alert about the occurrence of rhabdomyolysis when roxadustat is used.